Stem-cell company charged with hype
By Elie Dolgin Cross-posted from The Great Beyond US regulators accused a stem cell biotech company on Tuesday of inflating claims about an early stage cell therapy. The US Securities and Exchange Commission (SEC) charged Bothell, Washington-based CellCyte Genetics Corporation, along with its former chief executive and former chief scientific officer, with duping investors into believing that its experimental stem cell technology was nearing human trials. “CellCyte and its senior officers knew that it would take years of research to determine whether the stem cell discovery could be developed into a viable product,” said Marc Fagel, director of the SEC’s … Read more